Overview
Vision correction firm's Q4 net sales rose 18.1% yr/yr but missed analyst expectations
Net loss for Q4 narrowed compared to the previous year
Outlook
STAAR expects modest growth in China's in-market volume demand in 2026
Result Drivers
CHINA SALES - Growth in China drove overall net sales increase, despite inventory management challenges
GROSS MARGIN IMPROVEMENT - Gross margin rose due to cost reductions and timing of cost recognition from previous shipments
Company press release: ID:nBw6WVKSra
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Miss
$57.80 mln
$75.37 mln (9 Analysts)
Q4 EPS
-$0.37
Q4 Net Income
-$18.31 mln
Q4 Gross Margin
75.70%
Q4 Gross Profit
$43.74 mln
Q4 Operating Income
-$22.84 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 10 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for STAAR Surgical Co is $22.00, about 15.5% above its March 2 closing price of $19.05
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
